Global Antibiotics Position Steri-Pharma as a global supplier of parenteral cephalosporin products to US and international markets, highlighting cost-effective manufacturing, quality focus, and reliability to attract distributors and health systems.

Growth Footprint Target expansion opportunities tied to their announced $50M plant expansion in Syracuse and tax incentives, presenting capacity upgrades and longer-term supply security to potential contract manufacturers, CDMOs, and hospital networks seeking scalable production.

People Advantage Leverage their people-centric culture and skilled workforce as a differentiator in value propositions for employers of record, contract manufacturing partners, and supply chain collaborators seeking dependable operations and strong quality culture.

Cost Competitiveness Emphasize favorable pricing models, first-shift schedules, generous time off, and strong benefits to attract potential customers and distributors looking for cost-efficient parenteral antibiotic production without compromising quality.

Tech & Compliance Highlight the existing tech stack and regulatory-aligned manufacturing capabilities to engage IT-enabled procurement and compliance-focused buyers, while exploring opportunities for digitalizing quality systems and supplier integration.